Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Arrowhead vs. Rhythm

__timestampArrowhead Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.
Wednesday, January 1, 2014244195361213000
Thursday, January 1, 2015347180893425000
Friday, January 1, 2016409982096311000
Sunday, January 1, 2017320228809518000
Monday, January 1, 20181911005128080000
Tuesday, January 1, 20192655625736550000
Wednesday, January 1, 20205227589046125000
Friday, January 1, 20218098100068486000
Saturday, January 1, 202212443100092032000
Sunday, January 1, 202390932000117532000
Monday, January 1, 202498761000
Loading chart...

Unleashing the power of data

SG&A Cost Management: A Tale of Two Pharmaceuticals

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Arrowhead Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Arrowhead's SG&A expenses grew by approximately 300%, peaking in 2022. In contrast, Rhythm Pharmaceuticals saw a staggering increase of nearly 9,600% over the same period, with a notable spike in 2023. This dramatic rise highlights Rhythm's aggressive expansion strategy, while Arrowhead's steadier growth suggests a more controlled approach. However, the absence of data for Rhythm in 2024 leaves room for speculation about their future trajectory. As these companies navigate the complexities of the pharmaceutical industry, their ability to manage SG&A costs will be pivotal in determining their long-term success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025